Rhythm Pharmaceuticals Management
Management criteria checks 3/4
Rhythm Pharmaceuticals' CEO is David Meeker, appointed in Jul 2020, has a tenure of 3.83 years. total yearly compensation is $7.23M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 0.29% of the company’s shares, worth $7.64M. The average tenure of the management team and the board of directors is 3.5 years and 4.9 years respectively.
Key information
David Meeker
Chief executive officer
US$7.2m
Total compensation
| CEO salary percentage | 9.7% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.5yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$7m | US$705k | -US$185m |
| Sep 30 2023 | n/a | n/a | -US$186m |
| Jun 30 2023 | n/a | n/a | -US$182m |
| Mar 31 2023 | n/a | n/a | -US$181m |
| Dec 31 2022 | US$3m | US$652k | -US$181m |
| Sep 30 2022 | n/a | n/a | -US$181m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$166m |
| Dec 31 2021 | US$6m | US$630k | -US$70m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$15m | US$262k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$134m |
| Mar 31 2020 | n/a | n/a | -US$146m |
| Dec 31 2019 | US$287k | n/a | -US$141m |
| Sep 30 2019 | n/a | n/a | -US$133m |
| Jun 30 2019 | n/a | n/a | -US$115m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$282k | n/a | -US$74m |
| Sep 30 2018 | n/a | n/a | -US$59m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$268k | n/a | -US$38m |
Compensation vs Market: David's total compensation ($USD7.23M) is about average for companies of similar size in the US market ($USD6.66M).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
CEO
David Meeker (69 yo)
3.8yrs
Tenure
US$7,230,457
Compensation
Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.8yrs | US$7.23m | 0.29% $ 7.6m | |
| CFO & Treasurer | 6.8yrs | US$2.31m | 0.16% $ 4.3m | |
| Chief Technical Officer | 3.8yrs | US$1.74m | 0.000050% $ 1.3k | |
| Executive VP & Head of International | 3.6yrs | US$1.74m | 0.057% $ 1.5m | |
| Executive VP & Head of North America | 3.5yrs | US$2.11m | 0.011% $ 299.9k | |
| Corporate Controller | 1.2yrs | no data | 0.0013% $ 34.7k | |
| Head of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP & General Counsel | 3.5yrs | no data | no data | |
| Vice President of Sales & Marketing | no data | no data | no data | |
| Chief Human Resources Officer | 2.8yrs | no data | 0.049% $ 1.3m | |
| Senior VP & Head of Strategy | 2.3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1.7yrs | no data | no data |
3.5yrs
Average Tenure
51yo
Average Age
Experienced Management: RYTM's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.5yrs | US$7.23m | 0.29% $ 7.6m | |
| Corporate Controller | 1.2yrs | no data | 0.0013% $ 34.7k | |
| Independent Director | 4.9yrs | US$283.77k | 0% $ 0 | |
| Independent Director | 8.5yrs | US$308.77k | 0% $ 0 | |
| Lead Independent Director | 11.2yrs | US$328.77k | 0.0095% $ 252.4k | |
| Independent Director | 3.4yrs | US$298.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$301.27k | 0% $ 0 |
4.9yrs
Average Tenure
66yo
Average Age
Experienced Board: RYTM's board of directors are considered experienced (4.9 years average tenure).